Skip to content

Gait Control in Parkinson Disease

Flexible Control of Gait in Parkinson Disease: Effect of Task Instruction on the Exploitation of Redundancy in Speed Control.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05908279
Acronym
GAIT-PD
Enrollment
100
Registered
2023-06-18
Start date
2023-05-01
Completion date
2027-10-31
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

Previous work has shown that a statistical property of gait characterised by long-range autocorrelation functions is altered in Parkinson disease (PD). On the other hand it has been suggested that the same property is linked to the ability in healthy humans to co-regulate the amplitude and cadence of strides towards maintaining a constant speed. Here the investigators want to better understand why it is altered in PD by measuring the transitions between gait instructed by a metronome, and gait without metronome. The experimental conditions will allow the comparisons between these transitions across PD and healthy groups of volunteers, and assess differences based on statistical and computational modelling. The link with potential freezing episodes will also be studied to assess whether the statistical determinants of gait control in this population can be used as a proxy or predictor of the occurence of freezing episodes.

Interventions

Walk with and without a metronome

OTHERDisease assessement

Disease stage assessed by a doctor

Sponsors

Université Catholique de Louvain
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients and volunteers able to walk for 20mins and without other neurological disorders.

Exclusion criteria

* Patients or volunteers unable to walk for 20mins and with other neurological disorders.

Design outcomes

Primary

MeasureTime frameDescription
Stride cadenceMeasured during the entire experiment (an average of 4.5 years)Time between two consecutive heel strikes. Units are seconds.
Stride amplitudeMeasured during the entire experiment (an average of 4.5 years)Distance between two consecutive heel strikes. Units are meters.

Countries

Belgium

Contacts

Primary ContactAndré Mouraux, PhD
andre.mouraux@uclouvain.be+32 2 764 54 47
Backup ContactFrederic Crevecoeur
frederic.crevecoeur@uclouvain.be

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026